Nuformix PLC
LSE:NFX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nuformix PLC
Research & Development
Nuformix PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nuformix PLC
LSE:NFX
|
Research & Development
-£95.3k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Research & Development
-£6.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-8%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Research & Development
-$13.8B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-9%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Research & Development
-$151m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-15%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Research & Development
-£15.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-17%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Nuformix PLC
Glance View
Nuformix Plc is a pharmaceutical development company, which targets unmet medical needs in fibrosis and oncology via drug repurposing. The company is headquartered in Cambridge, Cambridgeshire and currently employs 3 full-time employees. The company went IPO on 2015-12-17. The firm focuses on medical needs in fibrosis and oncology using drug repurposing. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP001, is a form of the drug aprepitant that is marketed as a product in the oncology supportive care setting (chemotherapy induced nausea and vomiting). NXP002, is its pre-clinical lead asset and used for inhaled treatment for idiopathic pulmonary fibrosis (IPF). NXP004, is an oncology drug that is used for the treatment of several cancers. The firm's subsidiary is Nuformix Technologies Limited.
See Also
What is Nuformix PLC's Research & Development?
Research & Development
-95.3k
GBP
Based on the financial report for Sep 30, 2025, Nuformix PLC's Research & Development amounts to -95.3k GBP.
What is Nuformix PLC's Research & Development growth rate?
Research & Development CAGR 1Y
-34%
Over the last year, the Research & Development growth was -34%.
